Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes

Trial Profile

Prospective and randomized controlled study on the efficacy and safety of ipragliflozin and metformin to visceral fat reduction for the patients being treated with DPP-4 inhibitors for poor glycemic controlled type-2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Ipragliflozin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 12 May 2017 Planned End Date changed from 30 Apr 2017 to 12 May 2017.
    • 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top